In this special episode of the View, Dr. Deepak Bhatt and Prof. Philippe Gabriel Steg discuss Day 2 of ESC Congress 2019, including ticagrelor compared to placebo added to low-dose aspirin in patients with stale coronary artery disease (THEMIS and THEMIS-PCI); angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction and dapagliflozin and prevention of adverse outcomes in heart failure (PARAGON-HF and DAPA HF); revascularization with multivessel percutaneous coronary intervention in ST-segment elevation myocardial infarction (COMPLETE); and ticagrelor versus prasugrel in patients with acute coronary syndrome (ISAR-REACT 5).

Subscribe on iTunes | Subscribe on Google Play

Clinical Topics: Acute Coronary Syndromes, Cardiovascular Care Team, Heart Failure and Cardiomyopathies, Invasive Cardiovascular Angiography and Intervention, Prevention, Atherosclerotic Disease (CAD/PAD), Acute Heart Failure, Interventions and ACS, Interventions and Coronary Artery Disease, Interventions and Imaging, Angiography, Nuclear Imaging

Keywords: EaglesEyeView, ESC Congress, ESC 19, Adenosine, Primary Prevention, Angiography, Percutaneous Coronary Intervention, Diabetes Mellitus, Coronary Artery Disease, Angiotensins, Stroke Volume, Heart Failure, Diabetes Mellitus, Type 2, Stroke Volume, Heart Failure, Hospitalization, Glucosides, Benzhydryl Compounds, Cardiomyopathies, Myocardial Infarction, Percutaneous Coronary Intervention, Angiography, Acute Coronary Syndrome

< Back to Listings